GlassScriptPhysician profile
John Frontera
NPI 1194796268
$599.32
in general payments reported to CMS, 2019-2025
11 companies · $19.05 in 2025
The $19.05 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.63 · 2020: $19.42 · 2021: $158 · 2022: $217 · 2023: $20.97 · 2024: $82.75 · 2025: $19.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $122.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.40 | 2021-2025 | |
| Ucb, INC. | $66.39 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $55.28 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.11 | 2022 | |
| Amgen INC. | $29.98 | 2021 | |
| Acadia Pharmaceuticals INC | $25.98 | 2024 | Nuplazid |
| Eisai INC. | $23.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2020 | |
| Lilly USA, LLC | $16.60 | 2021 | |
| Kyowa Kirin, INC. | $14.18 | 2019 | |
| Emd Serono, INC. | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Frontera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.